Circular RNA Treatment Restores Saliva Flow in Patients
Early results from an RNA-based therapy trial show promise for repairing radiation-damaged salivary glands by mid-2027.
Updated on Oct. 22, 2026 in Biotech
Live Poll
Do you trust emerging genetic therapies to effectively treat chronic conditions like dry mouth?
RiboX Therapeutics has announced positive early-stage clinical trial results for its circular RNA treatment, RXRG001, which targets radiation-induced dry mouth. The FDA has also granted the experimental therapy Regenerative Medicine Advanced Therapy designation.
Why it matters
Radiation therapy for head and neck cancer frequently causes permanent damage to salivary glands, and this candidate represents a new approach to restoring gland function through RNA-based genetic programming.
RXRG001 uses lipid nanoparticles to deliver circular RNA that encodes the aquaporin-1 protein. The treatment demonstrated significant functional improvement in the low-dose cohort, with unstimulated saliva flow increasing by as much as 450% after three months.
The players
RiboX Therapeutics
A biotechnology firm specializing in circular RNA platform development for protein expression therapies.
FDA
The United States federal agency responsible for evaluating the safety and efficacy of new medical treatments.
The details
The treatment works by delivering circular RNA—a stable form of genetic code—into the body using lipid nanoparticles, which are microscopic fat bubbles used as drug delivery vehicles. This instructs surviving salivary epithelium cells to produce aquaporin-1, a membrane protein that facilitates water transport. By increasing the expression of these water channels, the treatment aims to restore the natural moisture-producing capacity of glands damaged by radiation.
Timeline
September 2026: FDA granted RMAT designation to RXRG001.
October 2026: Study findings published in the New England Journal of Medicine.
Mid-2027: Expected completion of the full clinical study.
The Tech Race
The study marks a shift in the race to apply circular RNA beyond vaccines toward direct organ function restoration. It follows the FDA's Regenerative Medicine Advanced Therapy designation program, positioning the therapy for potential accelerated development cycles.
This treatment is currently in research-stage trials and is not yet available for clinical use. Patients with radiation-induced dry mouth should continue to consult with their oncology specialists regarding standard supportive care options.
The takeaway
This RNA-based approach to restoring salivary gland function marks a significant departure from current palliative treatments. Watch for the full study results expected in mid-2027 to see if the therapeutic benefits persist at larger scales.
What happens next
The ongoing SPRINX-1 trial aims to expand enrollment to 42 patients, with a projected completion date by mid-2027.
Further reading
Learn more about the latest innovations in genetic medicine in our Biotech section.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you trust emerging genetic therapies to effectively treat chronic conditions like dry mouth?
